Table 4.
Diagnostic role of lncRNAs in CAD.
| LncRNA | Expression pattern | Sample | Type of marker | ROC curve analysis | References | ||
|---|---|---|---|---|---|---|---|
| Sensitivity | Specificity | Area under the curve (AUC) | |||||
| GAS5 | Down-regulated | Serum samples from 102 CAD patients and 98 control subjects | Diagnostic marker | 86.7% | 86.5% | 0.889 | (33) |
| HULC | Down-regulated | Blood samples from 50 premature CAD patients and 50 age- and gender-matched healthy volunteers as controls | Diagnostic marker | – | – | 0.90 | (18) |
| DICER1-AS1 | Down-regulated | Blood samples from 50 premature CAD patients and 50 age- and gender-matched healthy volunteers as controls | Diagnostic marker | – | – | 0.87 | (18) |
| CASC11 | Down-regulated | Plasma samples from 82 CAD patients and 82 age- and gender-matched healthy individuals | Diagnostic marker | – | – | 0.90 | (19) |
| ANRIL (EU741058) | Down-regulated | Blood samples from 50 CAD patients and 50 healthy volunteers | Diagnostic marker | 82% | 69% | – | (45) |
| IFNG-AS1 | Up-regulated | Plasma samples from 102 patients with CAD and 89 control subjects | Diagnostic marker (for prediction of CAD risk) | – | – | 0.755 | (15) |
| H19 | Up-regulated | Serum samples from 30 CAD patients and 30 healthy subjects | Diagnostic marker | – | – | 0.9367 | (13) |
| OTTHUMT00000387022 | Up-regulated | 246 CAD patients and 206 control subjects | Diagnostic marker | – | – | 0.920 | (34) |
| LncPPARδ | Up-regulated | 246 patients with CAD and 206 healthy subjects | Diagnostic marker | – | – | 0.727 | (14) |
| LncPPARδ along with CAD risk factors | Up-regulated | 246 patients with CAD and 206 healthy subjects | Diagnostic marker | – | – | 0.785 | |
| THRIL | Up-regulated | Plasma samples from 220 patients with coronary heart disease and 200 control individuals | Diagnostic marker | – | – | 0.869 | (36) |
| ANRIL | Up-regulated | Plasma samples from 125 CAD patients and 105 control individuals | Diagnostic marker | – | – | 0.789 | (44) |
| AC100865.1 | Up-regulated | Plasma samples from 256 patients with CAD and 222 healthy individuals | Diagnostic marker | – | – | 0.795 | (46) |
| ENST00000444488.1 | – | Blood samples [peripheral blood mononuclear cells (PBMCs)] from 505 CAD patients and 343 male individuals as controls | Diagnostic marker [distinguishing patients with acute myocardial infarction (AMI) form non-AMI patients] | – | – | 0.758 | (47) |
| ENST00000444488.1 | – | Blood samples (PBMCs) from 505 CAD patients and 343 male individuals as controls | Diagnostic marker (distinguishing patients with CAD from controls) | – | – | 0.799 | |
| uc010yfd.1 | – | Blood samples (PBMCs) from 505 CAD patients and 343 male individuals as controls | Diagnostic marker (distinguishing patients with CAD from controls) | – | – | 0.779 | |
| ENST00000444488.1 uc010yfd.1 | – | Blood samples (PBMCs) from 505 CAD patients and 343 male individuals as controls | Diagnostic marker (distinguishing patients with CAD from controls) | – | – | 0.851 | |
| ENST00000444488.1 uc010yfd.1 along with age, BMI, glucose, and HDL | – | Blood samples (PBMCs) from 505 CAD patients and 343 male individuals as controls | Diagnostic marker (distinguishing patients with CAD from controls) | – | – | 0.902 | |
| H19 | Up-regulated | Plasma samples from 300 CAD patients and 180 control individuals | Diagnostic marker | – | – | 0.631 | (48) |
| LIPCAR | Up-regulated | Plasma samples from 300 CAD patients and 180 control individuals | Diagnostic marker | – | – | 0.722 | |
| KCNQ1OT1 | Up-regulated | Blood samples (PBMCs) from 20 patients with CAD and 20 individuals without CAD | Diagnostic marker | – | – | 0.865 | (49) |
| HIF1A-AS2 | Up-regulated | Blood samples (PBMCs) from 20 patients with CAD and 20 individuals without CAD | Diagnostic marker | – | – | 0.852 | |
| APOA1-AS | Up-regulated | Blood samples (PBMCs) from 20 patients with CAD and 20 individuals without CAD | Diagnostic marker | – | – | 0.967 | |
|
KCNQ1OT1
HIF1A-AS2 APOA1-AS |
Up-regulated Up-regulated Up-regulated |
Blood samples (PBMCs) from 20 patients with CAD and 20 individuals without CAD | Diagnostic marker | – | – | 0.990 | |
| ENST00000512246.1 | Up-regulated | Blood samples from 173 CAD patients and 151 healthy controls | Diagnostic marker | 0.833 | 0.7 | 0.804 | (50) |
| TCONS_00023843 | Up-regulated | Blood samples from 173 CAD patients and 151 healthy controls | Diagnostic marker | 0.767 | 0.567 | 0.69 | |
| NR_028044.1 | Up-regulated | Blood samples from 173 CAD patients and 151 healthy controls | Diagnostic marker | 0.6 | 0.833 | 0.739 | |
| TCONS_00029157 | Up-regulated | Blood samples from 173 CAD patients and 151 healthy controls | Diagnostic marker | 0.667 | 0.833 | 0.769 | |
| MIAT | Up-regulated | Blood samples from 110 CAD patients and 117 volunteers as controls | Diagnostic marker | 95.5% | 72.7% | 0.888 | (51) |